Active, not recruitingNCT05718700
Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
Studying Hepatitis delta
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gilead Sciences
- Principal Investigator
- Gilead Study DirectorGilead Sciences
- Intervention
- Bulevirtide(drug)
- Enrollment
- 170 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- Medizinische Universität Graz Universitätsklinik für Innere Medizin, Klinische Abteilung für Gastroenterologie und Hepatologie, Graz, Austria
- Aö Landeskrankenhaus Hall, Hall in Tirol, Austria
- Universitätsklinik für Innere Medizin I Innsbruck, Innsbruck, Austria
- Medizinische Universitat Wien, Vienna, Austria
- Centre Hospitalier Universitaire D'Angers, Angers, France
- Hôpital Avicenne - APHP, Bobigny, France
- Hopital Beaujon, Clichy, France
- Hôpitaux Universitaires Henri Mondor, Créteil, France
- CHU Grenoble Alpes, Grenoble, France
- Centre Hospitalier Universitaire De Lille- Hôpital Huriez, Lille, France
- CHU de Limoges - Hopital Dupuytren, Limoges, France
- Hôpital de la Croix-Rousse, Lyon, France
- Hôpital Saint Eloit, Montpellier, France
- APHP Hôpital Pitié Salpêtrière, Paris, France
- Hôpital Haut-Lévêque, Pessac, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05718700 on ClinicalTrials.govOther trials for Hepatitis delta
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07454837Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideMirum Pharmaceuticals, Inc.
- RECRUITINGNCT07491848Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+DResearch Center of Periodontal-Systemic Interactions
- RECRUITINGPHASE3NCT07298330A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)Mirum Pharmaceuticals, Inc.
- RECRUITINGNCT07317011"Referral Attivo" Delta, Dallo Screening Alla Presa in Carico.FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGNCT07429864Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With BulvertideFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE3NCT07200908A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)Mirum Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT07142811A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionVir Biotechnology, Inc.
- RECRUITINGPHASE1, PHASE2NCT07096193Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta VirusGilead Sciences